Bristol Myers Squibb (BMY) Com Stk USD 0.10 (CDI)

Sell:$47.17Buy:$47.19$0.48 (1.03%)

Prices delayed by at least 15 minutes
Sell:$47.17
Buy:$47.19
Change:$0.48 (1.03%)
Deal now
Prices delayed by at least 15 minutes
Sell:$47.17
Buy:$47.19
Change:$0.48 (1.03%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.

Key people

Christopher S. Boerner
Chairman of the Board, Chief Executive Officer
David V. Elkins
Executive Vice President, Chief Financial Officer, Member of the Leadership Team
Benjamin Hickey
President - RayzeBio Organization, Member of the Leadership Team
Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
Amanda Poole
Executive Vice President, Chief People Officer, Member of the Leadership Team
Greg Scott Meyers
Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Robert Plenge
Executive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team
Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Theodore R. Samuels
Lead Independent Director
Peter J. Arduini
Independent Director
Deepak L. Bhatt
Independent Director
Julia A. Haller
Independent Director
Michael R. McMullen
Independent Director
Click to see more

Key facts

  • Shares in issue
    2.92bn
  • EPIC
    BMY
  • ISIN
    US1101221083
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $94.97bn
  • Employees
    34,100
  • Exchange
    New York Stock Exchange
  • Index
    S&P 500, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.